What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 144% in the afternoon session after its personalized mRNA cancer vaccine, develop...
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly r...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.1% year on year to $145 mi...
Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases.
The company posted a net loss of $782 million, or $1.97 per sha
